A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy?

@article{Rastinehad2009A2E,
  title={A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Gu{\'e}rin therapy?},
  author={Ardeshir R. Rastinehad and Michael Cecil Ost and Brian A. Vanderbrink and Kathryn L Z Greenberg and Assaad El-Hakim and Robert Marcovich and Gopal H. Badlani and Arthur D. Smith},
  journal={Urology},
  year={2009},
  volume={73 1},
  pages={27-31}
}
OBJECTIVES To determine whether there is an oncologic benefit of adjuvant bacillus Calmette Guérin (BCG) after resection of upper tract transitional cell carcinoma (UTTCC). METHODS A total of 133 renal units (RU) treated by percutaneous resection for UTTCC between 1985 and 2005 were retrospectively analyzed. Forty-four RU were excluded because of carcinoma in situ, high grade/stage, metastatic disease present at initial presentation, and/or the patient could tolerate loss of RU. Eighty-nine… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…